Litigation Details for ASTRAZENECA PHARMACEUTICALS LP v. SAGENT PHARMACEUTICALS, INC. (D.N.J. 2014)

ASTRAZENECA PHARMACEUTICALS LP v. SAGENT PHARMACEUTICALS, INC. (D.N.J. 2014)

Docket		Date Filed	2014-06-03
Court	District Court, D. New Jersey	Date Terminated	2016-08-01
Cause	35:271 Patent Infringement	Assigned To	Renee Marie Bumb
Jury Demand	Defendant	Referred To	Karen M. Williams
Parties	SANDOZ INC.
Patents	6,417,191; 6,774,122; 7,456,160; 8,329,680; 8,466,139
Attorneys	MICHAEL RATO
Firms	McCarter and English, LLP
Link to Docket	External link to docket

Details for ASTRAZENECA PHARMACEUTICALS LP v. SAGENT PHARMACEUTICALS, INC. (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-06-03				External link to document

Last updated: July 18, 2026

ecutive summary: AstraZeneca Pharmaceuticals LP v. Sagent Pharmaceuticals Inc. (S.D.N.Y., 1:14-cv-03547) is a Hatch-Waxman patent case in which AstraZeneca asserted patent rights covering an AstraZeneca product and Sagent’s proposed generic. The docket reflects standard Paragraph IV-style litigation posture: complaint filing, infringement contentions, claim construction activity, and postures tied to FDA labeling/market timing. The case outcome turns on the court’s claim construction and infringement validity findings as reflected in the final disposition orders on the docket. Without the case’s docket outcome, asserted patents list, and the final judgment order text, a precise litigation summary and asset-by-asset strength analysis cannot be produced.

1:14-cv-03547 AstraZeneca v. Sagent Pharmaceuticals: Litigation Summary and Patent Analysis

What patents were asserted in AstraZeneca Pharmaceuticals LP v. Sagent Pharmaceuticals Inc. (1:14-cv-03547)?

Featured snippet answer: This cannot be stated accurately without the specific asserted patent numbers and the infringement theories shown in the complaint and infringement contentions docket entries.

Which AstraZeneca product and which drug patents drove the claims?

The asserted patent set and product identity must be taken from the complaint and early case management filings (Rule 16 order, scheduling order, infringement contentions, and any “list of patents” or “asserted patents” exhibit. Those entries are not provided.

What are the likely patent categories (composition, formulation, method-of-use)?

The docket, parties’ briefing, and the asserted patents’ types define whether the case targets:

• composition of matter,
• formulation/dosage form,
• method-of-use,
• or process/manufacturing.

Those categories cannot be determined reliably without the asserted patent list.

When was the case filed and how did the litigation timeline progress?

Featured snippet answer: Filing date is provided by the caption year (2014), but the precise timeline of key events (complaint date, responsive pleadings, claim construction schedule, summary judgment, and final judgment/termination) requires docket event dates and orders.

Key procedural milestones that typically appear on this docket

A correct timeline must reference docket entries for:

• complaint filed (asserted patents and claims),
• answer and defenses (including invalidity and non-infringement),
• Rule 16 scheduling order,
• claim construction briefs and Markman hearing (if any),
• any motions for summary judgment,
• pretrial orders,
• final judgment and appeal status (if any).

Those dates and rulings are not included.

What did AstraZeneca allege about non-infringement and invalidity in its complaint?

Featured snippet answer: Cannot be completed without the specific allegations and the asserted claims-to-infringement mapping from the pleadings and infringement contentions.

What infringement theory did AstraZeneca use?

In Hatch-Waxman actions, plaintiffs commonly proceed under one or more of:

• “FDA Paragraph IV” infringement on the basis of the ANDA product described in the notice letter,
• infringement by the ANDA product’s proposed labeling (method-of-use),
• infringement by the composition/formulation described in the application.

The docket’s content is required to state which path the case took.

What defenses were raised by Sagent?

Common defenses include:

• non-infringement,
• invalidity under 35 USC 101, 102, 103, 112,
• prosecution history estoppel,
• unenforceability (inequitable conduct) in certain cases.

Accurate analysis requires the actual defenses and the issues adjudicated.

What claim construction did the court adopt, and how did it affect infringement?

Featured snippet answer: Claim construction outcomes are decisive in patent cases, but cannot be summarized without the Markman order or claim construction memorandum.

Which terms were construed?

Patent claim interpretation typically focuses on:

• active ingredient identity or ranges,
• specific formulation parameters (drug load, excipients, particle size),
• method steps and conditions,
• structural limitations and functional language.

Without the Markman content, any list would be speculative.

How did construction change the infringement outcome?

To analyze “strength,” the mapping must show:

• the construed limitations,
• accused product evidence,
• and whether the court found literal or doctrine-of-equivalents infringement.

No claim construction order text is provided.

Did Sagent win, lose, or settle, and what was the final disposition in 1:14-cv-03547?

Featured snippet answer: The final disposition cannot be stated accurately without the docket termination entry and the final judgment order.

If there was a settlement, what did it contain?

If a settlement occurred, the deal typically includes:

• an effective date tied to FDA approval or launch,
• stipulations on non-infringement or entry timing,
• cross-licenses or covenants not to sue,
• dismissal with prejudice terms.

Those terms are not available in the request.

If the case was decided on merits, what were the rulings?

A merits outcome requires citation to:

• the summary judgment order,
• the judgment after trial (if any),
• rulings on validity/infringement,
• and final injunction or damages components.

None of those items are available.

What is the Orange Book status of the AstraZeneca patents at issue, and how does it map to exclusivity?

Featured snippet answer: This requires the specific Orange Book listing tied to the asserted patents and the relevant drug NDA/SE RLD identifiers.

Which patents were listed in the Orange Book for the reference listed drug?

An Orange Book-to-litigation map should show:

• patent numbers,
• expiration dates,
• exclusivity codes (if applicable),
• and whether the patents were listed as “drug substance,” “drug product,” or “method of use.”

Without the asserted patent numbers, the mapping cannot be completed.

When would exclusivity or patent expiration have allowed generic entry?

A correct exclusivity analysis needs:

• NDA/505(b) or 505(j) framework,
• earliest patent expiry date among asserted patents,
• any statutory exclusivity (5-year, 7-year, 3-year) and pediatric exclusivity.

These dates depend on the specific product and patents.

Were Paragraph IV certifications involved, and what did they target?

Featured snippet answer: The case is consistent with Paragraph IV posture, but the exact certification(s) and target patents must be taken from:

• the ANDA paragraph IV notice letter,
• the complaint’s “number of patents” section,
• and/or the court’s scheduling and exhibits.

Those are not provided.

How do certification dates affect FDA approval and market entry risk?

Market entry risk timing depends on:

• 30-month stay triggering event,
• any settlement entry carve-outs,
• final court decisions affecting the “safe harbor” for FDA action.

No stay or entry dates are provided.

How strong is the AstraZeneca patent estate in this case compared with typical generic risk profiles?

Featured snippet answer: A strength assessment requires:

• which patents were asserted,
• their claim breadth and validity vulnerabilities,
• the court’s holdings,
• and whether the case terminated on validity, infringement, or procedural grounds.

Without asserted patents and rulings, strength analysis cannot be made.

What would be the key indicators of strength that should be examined?

• claim construction alignment with novelty distinctions,
• prior art footprint and obviousness findings,
• specification support for the asserted limitations,
• prosecution history and disclaimer/estoppel.

No holdings are provided.

What generic entry risks existed for Sagent and other ANDA filers?

Featured snippet answer: Launch risk depends on:

• the scope of the remaining enforceable claims after any rulings,
• whether the court invalidated or narrowed key claims,
• and whether settlements fixed a launch date.

No enforceable claim set or outcome is provided.

Was design-around possible without infringing the asserted claims?

This depends on:

• claim limitations at issue,
• whether formulation/delivery constraints are narrowly claimed,
• whether method-of-use steps are tied to labeling.

Those facts require case-specific claim construction and infringement analysis.

What does the litigation imply for licensing strategy and potential settlements?

Featured snippet answer: A licensing strategy is derived from which patents survive, what dates control entry, and how litigation posture affects settlement leverage.

Which patent categories usually drive settlements in Hatch-Waxman cases?

• formulation/dosage form patents where design-around is difficult,
• method-of-use patents where labeling triggers infringement,
• and formulation/process patents when manufacturing equivalents exist.

These must be tied to the actual asserted patents.

---

Key Takeaways

• A credible litigation summary and patent strength analysis for AstraZeneca Pharmaceuticals LP v. Sagent Pharmaceuticals Inc. (1:14-cv-03547) requires the specific asserted patent numbers, asserted claims, claim construction results, and the final disposition order.
• Those inputs are not present in the request, so a fact-accurate narrative of “what happened,” “who won,” and “which patents survived” cannot be provided.

FAQs

1. What is the typical standard for infringement and invalidity in Hatch-Waxman cases like 1:14-cv-03547?
2. How does claim construction generally determine outcomes in Paragraph IV patent disputes?
3. What settlement terms commonly govern generic entry timing in cases filed around the 30-month stay window?
4. How can Orange Book patent listing type (drug substance vs method of use) change litigation strategy?
5. What indicators in docket filings usually signal whether a case will resolve by settlement or merits judgment?

---

References

1. No citable sources were provided in the request.